Literature DB >> 1693265

Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype.

D Ribatti1, A Vacca, M Bertossi, G De Benedictis, L Roncali, F Dammacco.   

Abstract

Correlations of malignancy grade, immunologic phenotype and angiogenic capacity were studied in B-cell non-Hodgkin's lymphomas grafted onto chorioallantoic membranes of chicken embryos. The angiogenic response elicited by the tumors was significantly greater than the response to normal lymph nodes, but it did not correlate with either the malignancy grade or the immunologic phenotype of the tumors. The elevated angiogenic capacity of neoplastic tissues is confirmed. The results also suggest that the extensive vasoproliferative response required by a rapidly growing tumor is not only controlled by the neoplastic cell population but, probably, by the host-response as well.

Entities:  

Mesh:

Year:  1990        PMID: 1693265

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  New molecular targets for treatment of lymphoma.

Authors:  Barbara Pro; Anas Younes
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

2.  Angiogenesis in nodal B cell lymphomas: a high throughput study.

Authors:  Alexandar Tzankov; Simone Heiss; Stephanie Ebner; William Sterlacci; Georg Schaefer; Florian Augustin; Michael Fiegl; Stephan Dirnhofer
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

Review 3.  Antiangiogenesis as a novel therapeutic concept in pediatric oncology.

Authors:  L Schweigerer
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

4.  A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma.

Authors:  A Vacca; R Di Stefano; A Frassanito; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

Review 5.  Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Authors:  Michelle A Fanale; Anas Younes
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

7.  The CAM Assay as an Alternative In Vivo Model for Drug Testing.

Authors:  Regine Schneider-Stock; Domenico Ribatti
Journal:  Handb Exp Pharmacol       Date:  2021

Review 8.  Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth.

Authors:  Lutz Menzel; Uta E Höpken; Armin Rehm
Journal:  Front Immunol       Date:  2020-12-03       Impact factor: 7.561

9.  The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma.

Authors:  Marcel Klingenberg; Jürgen Becker; Sonja Eberth; Dieter Kube; Jörg Wilting
Journal:  BMC Cancer       Date:  2014-05-18       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.